Svenska
Boston
An independent LDT provider
Home
Press releases
Reports & Presentations
Stock information
Home
Stock information
Learn more
The Share
Stock information
The Share
Learn more
Share capital development
PDMR transactions
Ownership structure
Analysts
Governance
Home
Governance
Learn more
General meetings
Board of Directors
Management team
Governance report
Nomination committee
External auditors
Remuneration committee
Internal control
Articles of association
Sustainability Report
Rights issue 2023
Prospectuses
Home
Prospectuses
Learn more
Listing transfer (2018)
Rights Issue (2016)
Listing (2015)
Financial targets
Calendar
IR Contact
Home
IR Contact
Learn more
Subscribe
Subscribe
English
Svenska
NOTE:
Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:
https://rb.gy/09bxx
Press releases
Show
All
Regulatory
R = Regulatory
May 26, 2023
Bulletin from the Annual General Meeting in Immunovia AB
R
May 23, 2023
Immunovia Publishes Interim Report for January-March 2023
R
May 22, 2023
Changes to the Nomination Committee’s proposal to the Annual...
R
May 17, 2023
Invitation to Immunovia’s Q1 presentation
May 6, 2023
The board member Philipp von Hugo resigns from Immunovia’s...
R
April 29, 2023
Immunovia AB appoints new CEO
R
April 26, 2023
Immunovia to discuss adoption of IMMrayTM PanCan-d with key opinion...
April 25, 2023
CONVENING NOTICE – ANNUAL GENERAL MEETING IN IMMUNOVIA AB (publ)
R
April 21, 2023
Immunovia publishes the annual report for 2022
R
April 20, 2023
Immunovia to participate in National Pancreas Foundation Webinar on...
April 12, 2023
Immunovia announces outcome of the rights issue
R
March 17, 2023
Immunovia publishes prospectus relating to the rights issue
R
<
1
2
3
4
…
7
>
Home
Archives for jonas.kaas
Page 2
